Cargando…

Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis

BACKGROUND: Primary Sjögren’s syndrome (pSS) and breast cancer are a highly prevalent autoimmune disease and malignancy, respectively, both occurring predominantly in females. Whether there is a link between these two diseases is uncertain. We conducted a systematic review and meta-analysis to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jian, Liu, Mengsi, Xiao, Ruoyi, Wang, Jin, Liao, Xibei, Ye, Zhen, Sun, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283727/
https://www.ncbi.nlm.nih.gov/pubmed/35844507
http://dx.doi.org/10.3389/fimmu.2022.904682
_version_ 1784747389792288768
author Deng, Jian
Liu, Mengsi
Xiao, Ruoyi
Wang, Jin
Liao, Xibei
Ye, Zhen
Sun, Zhen
author_facet Deng, Jian
Liu, Mengsi
Xiao, Ruoyi
Wang, Jin
Liao, Xibei
Ye, Zhen
Sun, Zhen
author_sort Deng, Jian
collection PubMed
description BACKGROUND: Primary Sjögren’s syndrome (pSS) and breast cancer are a highly prevalent autoimmune disease and malignancy, respectively, both occurring predominantly in females. Whether there is a link between these two diseases is uncertain. We conducted a systematic review and meta-analysis to investigate the risk, incidence, and mortality of breast cancer in patients with pSS. METHODS: We systematically searched Embase, PubMed, and Web of Science on January 31, 2022 to identify the study that assessed risk, incidence, or mortality of breast cancer in pSS. The fixed or random-effects models were applied to pool the effect estimates based on heterogeneity measured by Cochran’s Q-test and Higgins’ I(2). RESULTS: Ten studies involving 725,805 participants and 64,836 pSS patients were included in our analysis. The pooled result showed that, overall, pSS was not associated with the risk (SIR=0.92, 95%CI: 0.66-1.29, P=0.646) and mortality (HR = 0.78, 95%CI: 0.26-2.34, P = 0.664) of breast cancer; however, when stratified by geographic region, we found that patients with pSS in Asian countries (SIR=1.32, 95%CI: 1.10-1.58, P=0.003) and Argentina (SIR=3.76, 95%CI: 1.04-9.45, P=0.019) had an elevated risk of breast cancer, while pSS in Europe was associated with a reduced risk (SIR=0.61, 95%CI: 0.51-0.73, P<0.001). The pooled result from 28,635 female pSS patients indicated that the incidence of breast cancer was 2.15 (95% CI: 1.33-3.50) per 1000 person/years. CONCLUSION: This study suggests that there may be geographical differences in the association between pSS and breast cancer risk; patients with pSS in European countries are associated with a lower risk of breast cancer, while Asia and Argentina are the opposite. Future research is needed to further characterize the effect of pSS on breast cancer risk and the pathophysiological mechanisms underlying this association to unravel the complex relationship between the two.
format Online
Article
Text
id pubmed-9283727
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92837272022-07-16 Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis Deng, Jian Liu, Mengsi Xiao, Ruoyi Wang, Jin Liao, Xibei Ye, Zhen Sun, Zhen Front Immunol Immunology BACKGROUND: Primary Sjögren’s syndrome (pSS) and breast cancer are a highly prevalent autoimmune disease and malignancy, respectively, both occurring predominantly in females. Whether there is a link between these two diseases is uncertain. We conducted a systematic review and meta-analysis to investigate the risk, incidence, and mortality of breast cancer in patients with pSS. METHODS: We systematically searched Embase, PubMed, and Web of Science on January 31, 2022 to identify the study that assessed risk, incidence, or mortality of breast cancer in pSS. The fixed or random-effects models were applied to pool the effect estimates based on heterogeneity measured by Cochran’s Q-test and Higgins’ I(2). RESULTS: Ten studies involving 725,805 participants and 64,836 pSS patients were included in our analysis. The pooled result showed that, overall, pSS was not associated with the risk (SIR=0.92, 95%CI: 0.66-1.29, P=0.646) and mortality (HR = 0.78, 95%CI: 0.26-2.34, P = 0.664) of breast cancer; however, when stratified by geographic region, we found that patients with pSS in Asian countries (SIR=1.32, 95%CI: 1.10-1.58, P=0.003) and Argentina (SIR=3.76, 95%CI: 1.04-9.45, P=0.019) had an elevated risk of breast cancer, while pSS in Europe was associated with a reduced risk (SIR=0.61, 95%CI: 0.51-0.73, P<0.001). The pooled result from 28,635 female pSS patients indicated that the incidence of breast cancer was 2.15 (95% CI: 1.33-3.50) per 1000 person/years. CONCLUSION: This study suggests that there may be geographical differences in the association between pSS and breast cancer risk; patients with pSS in European countries are associated with a lower risk of breast cancer, while Asia and Argentina are the opposite. Future research is needed to further characterize the effect of pSS on breast cancer risk and the pathophysiological mechanisms underlying this association to unravel the complex relationship between the two. Frontiers Media S.A. 2022-07-01 /pmc/articles/PMC9283727/ /pubmed/35844507 http://dx.doi.org/10.3389/fimmu.2022.904682 Text en Copyright © 2022 Deng, Liu, Xiao, Wang, Liao, Ye and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Deng, Jian
Liu, Mengsi
Xiao, Ruoyi
Wang, Jin
Liao, Xibei
Ye, Zhen
Sun, Zhen
Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
title Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
title_full Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
title_fullStr Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
title_full_unstemmed Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
title_short Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
title_sort risk, incidence, and mortality of breast cancer in primary sjögren’s syndrome: a systematic review and meta-analysis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283727/
https://www.ncbi.nlm.nih.gov/pubmed/35844507
http://dx.doi.org/10.3389/fimmu.2022.904682
work_keys_str_mv AT dengjian riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis
AT liumengsi riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis
AT xiaoruoyi riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis
AT wangjin riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis
AT liaoxibei riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis
AT yezhen riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis
AT sunzhen riskincidenceandmortalityofbreastcancerinprimarysjogrenssyndromeasystematicreviewandmetaanalysis